CINECA IRIS Institutional Research Information System

CAMANNI, Franco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.838
EU - Europa 3.149
AS - Asia 2.817
AF - Africa 27
Continente sconosciuto - Info sul continente non disponibili 2
SA - Sud America 2
OC - Oceania 1
Totale 9.836
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.679
CN - Cina 2.163
SE - Svezia 543
UA - Ucraina 475
IE - Irlanda 457
DE - Germania 369
FR - Francia 320
SG - Singapore 277
KR - Corea 276
FI - Finlandia 268
GB - Regno Unito 233
IT - Italia 231
CA - Canada 159
PL - Polonia 90
RU - Federazione Russa 63
VN - Vietnam 53
AT - Austria 33
GR - Grecia 28
MU - Mauritius 19
NL - Olanda 15
PH - Filippine 12
BE - Belgio 11
SN - Senegal 8
HK - Hong Kong 7
IN - India 7
UZ - Uzbekistan 6
IR - Iran 5
LV - Lettonia 4
TR - Turchia 4
ME - Montenegro 3
ES - Italia 2
EU - Europa 2
IL - Israele 2
JP - Giappone 2
AU - Australia 1
BG - Bulgaria 1
BR - Brasile 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
ID - Indonesia 1
NO - Norvegia 1
PK - Pakistan 1
SA - Arabia Saudita 1
UY - Uruguay 1
Totale 9.836
Salva come PNG Salva come JPEG
Città #
Beijing 2.049
Chandler 579
Dublin 456
Santa Clara 387
Houston 241
Jacksonville 235
Singapore 211
Medford 197
Princeton 166
Villeurbanne 166
Columbus 123
Ann Arbor 118
Toronto 113
Milan 111
Nyköping 105
Dearborn 97
Warsaw 89
Boardman 83
Wilmington 81
Ashburn 80
Verona 63
Lachine 40
Dong Ket 38
Woodbridge 37
Fairfield 34
Vienna 33
Detroit 32
Fremont 30
Falls Church 27
Philadelphia 22
Norwalk 20
Boston 18
Chicago 15
San Mateo 13
Athens 12
Guangzhou 11
Hangzhou 11
Mountain View 11
Tappahannock 10
Brussels 9
Hefei 9
Kunming 8
Nanjing 8
Redwood City 8
Hebei 7
Pune 6
Cambridge 5
Moscow 5
Washington 5
Hong Kong 4
Munich 4
Nanchang 4
Redmond 4
Riga 4
Torino 4
Auburn Hills 3
Avigliana 3
Central 3
Düsseldorf 3
Edinburgh 3
Guiyang 3
New York 3
Seoul 3
Shanghai 3
Shenyang 3
Windsor 3
Zhengzhou 3
Amsterdam 2
Changchun 2
Chengdu 2
Eksjoe 2
Helsinki 2
Jinan 2
Los Angeles 2
Mahón 2
Ningbo 2
Ottawa 2
Salisbury 2
Seocho 2
Shenzhen 2
Silver Spring 2
Soissons 2
Turin 2
University Park 2
Wuhan 2
Xiamen 2
Atlanta 1
Baotou 1
Bergamo 1
Brampton 1
Campomarino 1
Centrale 1
Chelyabinsk 1
Chongqing 1
Copenhagen 1
Costa Mesa 1
Decatur 1
Den Haag 1
Des Moines 1
Dundrum 1
Totale 6.346
Salva come PNG Salva come JPEG
Nome #
Alprazolam, a benzodiazepine, does not modify the ACTH and cortisol response to hCRH and AVP, but blunts the cortisol response to ACTH in humans. 148
Arginine reinstates the somatotrope responsiveness to intermittent growth hormone-releasing hormone administration in normal adults. 134
Arginine potentiates but does not restore the blunted growth hormone response to growth hormone-releasing hormone in obesity. 133
Acute administration of recombinant human growth hormone inhibits the somatotrope responsiveness to growth hormone-releasing hormone in childhood. 131
Diagnosis of GH deficiency in adults. 123
Interactions of galanin and arginine on growth hormone, prolactin, and insulin secretion in man. 122
Arginine and growth hormone-releasing hormone restore the blunted growth hormone-releasing activity of hexarelin in elderly subjects. 117
The enhancing effect of pyridostigmine on the GH response to GHRH undergoes an accelerated age-related reduction in Down syndrome. 116
Acute clonidine administration potentiates spontaneous diurnal, but not nocturnal, growth hormone secretion in normal short children. 115
Human aging and the GH-IGF-I axis. 114
GH response to GHRH combined with pyridostigmine or arginine in different conditions of low somatotrope secretion in adulthood: obesity and Cushing's syndrome in comparison with hypopituitarism. 113
Blunted GH response to growth hormone-releasing hormone (GHRH) alone or combined with arginine in non-insulin-dependent diabetes mellitus. 113
Arginine abolishes the inhibitory effect of glucose on the growth hormone response to growth hormone-releasing hormone in man. 112
Comparison between insulin-induced hypoglycemia and growth hormone (GH)-releasing hormone + arginine as provocative tests for the diagnosis of GH deficiency in adults. 110
[Neuroregulation of GH secretion in aging] 109
Pirenzepine decreases basal and stimulated GH secretion in patients with type 2 (non-insulin-dependent) diabetes mellitus. 109
Age-related growth hormone-releasing activity of growth hormone secretagogues in humans. 108
Repeated administration of growth hormone-releasing hormone with or without previous administration of pyridostigmine in insulin-dependent diabetes mellitus. 108
Inhibition by salbutamol of GHRH-induced GH release in type 1 diabetes mellitus. 108
Growth hormone (GH) responsiveness to combined administration of arginine and GH-releasing hormone does not vary with age in man. 108
Pazienti pediatrici in trattamento con ormone somatotropo in Piemonte: primi dati del Registro Piemontese 106
Comparison of Monotard and Ultratard insulin at bedtime in a model of optimized insulin therapy in Italy. 104
Reproducibility of the growth hormone response to stimulation with growth hormone-releasing hormone plus arginine during lifespan. 103
The IGF-I response to very low rhGH doses is preserved in human aging. 102
Comparison of the potentiating effect of pyridostigmine, arginine and propranolol on the GHRH-induced GH release in short children. 101
Arginine but not pyridostigmine, a cholinesterase inhibitor, enhances the GHRH-induced GH rise in patients with anorexia nervosa. 100
Growth hormone-releasing peptides. 100
Pyridostigmine partially restores the GH responsiveness to GHRH in normal aging. 100
Enhanced adrenocorticotrophic hormone and cortisol responses to corticotrophin-releasing hormone in central idiopathic diabetes insipidus. 99
Repetitive GHRH administration fails to increase the response to GHRH in obese subjects. Evidence for a somatotrope defect in obesity? 98
Acute administration of pyridostigmine and clonidine has an additive stimulatory effect on GH release in normal children. 98
Comparison of growth hormone-releasing effect of growth hormone-releasing hormone, clonidine and pyridostigmine in normal children and adolescents. GH-releasing effect of GHRH, clonidine and pyridostigmine. 97
Somatotrope responsiveness to Hexarelin, a synthetic hexapeptide, is refractory to the inhibitory effect of glucose in obesity. 97
Metabolic modulation of the growth hormone-releasing activity of hexarelin in man. 94
Arginine enhances the growth hormone-releasing activity of a synthetic hexapeptide (GHRP-6) in elderly but not in young subjects after oral administration. 94
Orally active growth hormone secretagogues: state of the art and clinical perspectives. 93
Growth hormone secretion in Alzheimer's disease: studies with growth hormone-releasing hormone alone and combined with pyridostigmine or arginine. 92
Effects of direct and indirect acetylcholine receptor agonists on growth hormone secretion in humans. 91
The altered plasma amino acid pattern is responsible for the paradoxical growth hormone response to the oral glucose tolerance test in liver cirrhosis. 91
Interaction of free fatty acids and arginine on growth hormone secretion in man. 91
Biologic activities of growth hormone secretagogues in humans. 90
Dose-response study of GH effects on circulating IGF-I and IGFBP-3 levels in healthy young men and women. 89
Growth hormone-releasing activity of growth hormone-releasing peptide-6 is maintained after short-term oral pretreatment with the hexapeptide in normal aging. 89
Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH. 89
Modulation of growth hormone-releasing activity of hexarelin in man. 88
Effect of cholinergic enhancement by pyridostigmine on growth hormone secretion in obese adults and children. 88
Short-term administration of intranasal or oral Hexarelin, a synthetic hexapeptide, does not desensitize the growth hormone responsiveness in human aging. 88
Effects of beta-adrenergic agonists and antagonists on the growth hormone response to growth hormone-releasing hormone in anorexia nervosa. 86
Interaction of salbutamol with pyridostigmine and arginine on both basal and GHRH-stimulated GH secretion in humans. 86
Hypopituitaric patients with corticotropin insufficiency show marked impairment of the cortisol response to ACTH (1-24) independently of the duration of the disease. 86
Neuroactive drugs in growth disorders 86
The GH-releasing effect of Hexarelin, a synthetic hexapeptide, in newborns is lower than in young adults. 85
GH response to GHRH combined with pyridostigmine or arginine in different conditions of low somatotrope secretion in adulthood: obesity and Cushing's syndrome in comparison with hypopituitarism. 84
Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man. 84
Involvement of brain catecholamines and acetylcholine in growth hormone hypersecretory states. Pathophysiological, diagnostic and therapeutic implications. 84
New approach to the diagnosis of growth hormone deficiency in adults. 84
Interaction of salbutamol and galanin on both basal and growth hormone releasing hormone-stimulated growth hormone secretion in humans. 84
CORTICOTROPH AND ADRENAL RESPONSIVENESS TO hCRH, HEXARELIN AND ACTH IN YOUNG AND ELDERLY SUBJECTS 84
[Growth hormone and lipids] 83
Effects of histaminergic antagonists on the GH-releasing activity of GHRH or hexarelin, a synthetic hexapeptide, in man. 82
Pirenzepine blunts the nocturnal growth hormone release in insulin dependent diabetes. 81
Growth hormone response to GHRH during lifespan. 80
Influence of beta-adrenergic agonists and antagonists on the GH-releasing effect of Hexarelin in man. 80
Effect of galanin on basal and stimulated secretion of prolactin, gonadotropins, thyrotropin, adrenocorticotropin and cortisol in humans. 79
Chronic treatment with pirenzepine decreases growth hormone secretion in insulin-dependent diabetes mellitus. 79
Repeated GH-releasing hormone administration unravels different GH secretory patterns in normal adults and children. 78
A new approach in the evaluation of gonadotropins for the diagnosis of polycystic ovary syndrome. 78
EFFECT OF SHORT TERM ADMINISTRATION OF LOW RHGH DOSE ON IGF-I LEVELS AS FUNCTION OF SEX, AGE AND PATHOPHYSIOLOGICAL CONDITIONS 78
Neurotransmitter control of growth hormone secretion in humans. 77
Mechanisms underlying the negative growth hormone (GH) autofeedback on the GH-releasing effect of hexarelin in man. 77
Effects of alpha- and beta-adrenergic agonists and antagonists on growth hormone secretion in man. 76
Galanin reinstates the growth hormone response to repeated growth hormone-releasing hormone administration in man. 75
Effect of the potentiation of cholinergic activity on the variability in individual GH response to GH-releasing hormone. 75
Use of the Diabetes Risk Score for Opportunistic Screening of Undiagnosed Diabetes and Impaired Glucose Tolerance: The IGLOO (Impaired Glucose Tolerance and Long-Term Outcomes Observational) study 75
Low hexarelin dose and pyridostigmine have additive effect and potentiate to the same extent the GHRH-induced GH response in man. 74
Low dose orally administered arginine is able to enhance both basLow dose orally administered arginine is able to enhance both basal and growth hormone-releasing hormone-induced growth hormone secretion in normal short children. 73
Three-hour spontaneous GH secretion profile is as reliable as oral glucose tolerance test for the diThree-hour spontaneous GH secretion profile is as reliable as oral glucose tolerance test for the diagnosis of acromegaly. 72
The cut-off limits of the GH response to GH-releasing hormone-arginine test related to body mass index 71
Growth hormone secretagogues as corticotrophin-releasing factors. 69
Adrenocorticotropin- and cortisol-releasing effect of hexarelin, a synthetic growth hormone-releasing peptide, in normal subjects and patients with Cushing's syndrome. 68
Galanin positively modulates prolactin secretion in normal women. 67
Adrenocorticotropin and cortisol hyperresponsiveness to hexarelin in patients with Cushing's disease bearing a pituitary microadenoma, but not in those with macroadenoma. 66
ACTH-RELEASING EFFECTS OF HEXARELIN, A PEPTIDYL GH SECRETAGOGUE, IN NORMAL SUBJECTS PRETREATED WITH METYRAPONE OR RU486, A GLUCOCORTICOID RECEPTOR ANTAGONIST, AND IN PATIENTS WITH ADDISON'S DISEASE 66
Relationships between IGF-I and age, gender, body mass, fat distribution, metabolic and hormonal variables in obese patients. 66
EFFECT OF HEXARELIN, A SYNTHETIC GHRP, AND/OR hCRH ON ACTH- AND CORTISOL SECRETION IN NORMAL SUBJECTS AND IN PATIENTS WITH CUSHING’S SYNDROME 65
Hexarelin, a synthetic growth-hormone releasing peptide, shows no interaction with corticotropin-releasing hormone and vasopressin on adrenocorticotropin and cortisol secretion in humans. 64
Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone. 64
Endocrine responses to GH secretagogues in relation to sex and age in humans 63
THE INHIBITORY EFFECT OF ALPRAZOLAM, A BENZODIAZEPINE, OVERRIDES THE STIMULATORY EFFECT OF METYRAPONE-INDUCED LACK OF NEGATIVE CORTISOL FEED BACK ON CORTICOTROPH SECRETION IN HUMANS 63
Blockade of hp-GRF-40-induced GH release in normal men by a cholinergic muscarinic antagonist. 62
Arginine-induced hypophosphatemia and hyperkaliemia in man. 62
Hexarelin, a synthetic growth hormone releasing peptide, stimulates prolactin secretion in acromegalic but not in hyperprolactinaemic patients. 61
Growth hormone responses to pyridostigmine in normal adults and in normal and short children. 60
Stimulatory effect of adrenocorticotropin on cortisol, aldosterone, and dehydroepiandrosterone secretion in normal humans: dose-response study. 59
Prolonged treatment with glycerophosphocoline, an acetylcholine precursor, does not disclose the potentiating effect of cholinesterase inhibitors on GHRH-induced somatotroph secretion in anorexia nervosa. 59
Reduction of the somatotrope responsiveness to GHRH and Hexarelin but not to arginine plus GHRH in hyperprolactinemic patients. 58
GH but not IGF-I hypersecretion in acromegaly is generally attenuated in elderly acromegalics. 57
STIMULATORY EFFECTS OF HEXARELIN, A SYNTHETIC GHRP, ON ACTH AND CORTISOL SECRETION: STUDIES IN NORMAL SUBJECTS AND IN PATIENTS WITH CUSHING’S SYNDROME 56
Effects of dexamethasone and alprazolam, a benzodiazepine, on the stimulatory effect of hexarelin, a synthetic GHRP, on ACTH, cortisol and GH secretion in humans. 54
Estrogenic treatment does not modify the TSH and PRL responses to domperidone and TRH in patients with tumoral hyperprolactinemia. 54
Totale 8.762
Salva come PNG Salva come JPEG
Categoria #
all - tutte 30.966
article - articoli 0
book - libri 0
conference - conferenze 1.739
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 32.705
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020682 0 0 0 0 0 259 118 32 116 71 79 7
2020/2021889 83 14 104 47 120 39 77 22 140 108 44 91
2021/2022963 11 17 50 22 50 16 154 51 34 102 134 322
2022/20231.688 215 67 18 206 191 480 137 84 156 21 88 25
2023/2024529 109 107 16 35 33 45 5 24 0 10 43 102
2024/2025892 11 60 13 163 592 53 0 0 0 0 0 0
Totale 10.151